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PerspectiveThe term “bioequivalence” refers to pharmaceutically equivalent products where the extent of bioavailability of the actives are not 
significantly (in the statistical sense) different under scientific 
conditions usually following the rules of scientific sampling. As a student 
of the famous W.E. Deming (1900-1993) these words are common 
knowledge to people and researchers like me. To those not attuned 
to scientific sampling, these methods and the term bioequivalence 
would have no meaning. With strong backing by agencies involved in the testing of new pharmaceuticals and retesting of established drugs 
(both generic and proprietary) created by “perfect” law, the results 
will always be sound and scientifically justifiable.In the United States, agencies of government are working to keep the creation of new pharmaceuticals safe and useful in both the diagnosis and treatment of a huge number of health 
treatment and diagnostic problems. In the common sense of the 
term bioequivalence, society would feel confident that two or more pharmaceuticals are equivalent if their characteristics and purpose 
of curing the same treatment or diagnosis in the very same manner. 
Two or more pharmaceuticals if examined scientifically may show 
results that cannot be found statistically different. If that occurs the 
two or more drugs would be bioequivalent. Perfect law would have 
the purpose of establishing the scientific system for such a process. 
Those who dispute this have several arguments. Law may not be 
“perfect” and imperfect law creates conflict in the interpretation of 
the law and its eventual execution. We live in a society where law 
governs and to which we call “living law.” Hence, science advances the 
 
development and creates bioequivalent pharmaceuticals. Also, creates and develops testing methods employed by agencies of government to produce safety in usage and effects of pharmaceuticals and also 
in the use bioequivalent products. Last, using phrases like increase bioequivalence makes no sense from a sampling and testing point of 
view. Borrowing from previous scientific work, we can if two products 
are equivalent in every manner they cannot be different in anyway. If sampling differences are found, then we must determine if the 
difference is sufficiently large as to conclude that sampling variation cannot explain the small differences in the samples observed and 
analyzed. Monitoring results of tests is important to make certain that two products that found to be different come from separate and not 
equal populations.
Bioavailability refers to the extent to which a pharmaceutical 
reaches its site of action or a biological fluid such as blood that can access 
to its site of action. The two terms bioequivalence and bioavailability 
do not mean the same. Bioavailability is a subcategory of absorption and is the percentage of an administered dose of a product or drug that 
reaches circulation. This is a property of a drug and is part of principal 
pharma kinetic characteristics of pharmaceuticals. By definition, when a medication is administered intravenously, its bioavailability 
is 100%. Hence bioavailability and bio equivalence have different meaning and one can speak in terms of percentages of bioavailability 
but one cannot speak in terms percentages of bioequivalence. These are important concepts to understand whenever one analyzes large 
data sets sampled from populations. 
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